nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

17.07.2023 | Research

The elusive Luminal B breast cancer and the mysterious chemokines

verfasst von: Rogério Agenor de Araújo, Felipe Andrés Cordero da Luz, Eduarda da Costa Marinho, Camila Piqui Nascimento, Thais Rezende Mendes, Etelvina Rocha Tolentino Mosca, Lara de Andrade Marques, Patrícia Ferreira Ribeiro Delfino, Rafael Mathias Antonioli, Ana Cristina Araújo Lemos da Silva, Maria Luiza Gonçalves dos Reis Monteiro, Morun Bernardino Neto, Marcelo José Barbosa Silva

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 14/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Invasive ductal breast cancer (IDC) is heterogeneous. Staging and immunohistochemistry (IH) allow for effective therapy but are not yet ideal. Women with Luminal B tumors show an erratic response to treatment. This prospective study with 81 women with breast cancer aims to improve the prognostic stratification of Luminal B patients.

Methods

This is a prospective translational study with 81 women with infiltrating ductal carcinoma, grouped by TNM staging and immunohistochemistry, for survival analysis, and their correlations with the chemokines. Serum measurements of 13 chemokines were performed, including 7 CC chemokines [CCL2(MCP1), CCL3(MIP1α), CCL4(MIP1β), CCL5(Rantes), CCL11(Eotaxin), CCL17(TARC), CCL20(MIP3α)], 6 CXC chemokines [CXCL1(GroAlpha), CXCL5(ENA78), CCXCL8(IL-8), CXCL9(MIG), CXCL10(IP10), CXCL11(ITAC)].

Results

Overall survival was significantly dependent on tumor staging and subtypes by immunohistochemistry, with a median follow-up time the 32.87 months (3.67–65.63 months). There were age correlations with IP10/CXCL10 chemokines (r = 0.4360; p = 0.0079) and TARC/CCL17 (Spearman + 0.2648; p = 0.0360). An inverse correlation was found between body weight and the chemokines Rantes/CCL5 (r = − 0.3098; p = 0.0169) and Eotaxin/CCL11 (r = − 0.2575; p = 0.0470). Smokers had a higher concentration of MIP3α/CCL20 (Spearman + 0.3344; p = 0.0267). Luminal B subtype patients who expressed lower concentrations of ENA78/CXCL5 (≤ 254.83 pg/ml) (Log-Rank p = 0.016) and higher expression of MIP1β/CCL4 (> 34.84 pg/ml) (Log-Rank p = 0.014) had a higher risk of metastases.

Conclusion

Patients with Luminal B breast tumors can be better stratified by serum chemokine expression, suggesting that prognosis is dependent on biomarkers other than TNM and IH.

Nur mit Berechtigung zugänglich

Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P (2020) Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open 3:e2013226. https://doi.org/10.1001/jamanetworkopen.2020.13226CrossRefPubMedPubMedCentral

Ali S, Lazennec G (2007) Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26:401–420. https://doi.org/10.1007/s10555-007-9073-zCrossRefPubMedPubMedCentral

Amin MB et al (eds) (2017) AJCC cancer staging manual. Springer International Publishing, Cham. https://doi.org/10.1007/978-3-319-40618-3CrossRef

Becerra-Chauca N, Nieto-Gutierrez W, Taype-Rondan A (2022) 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting. Lancet Oncol 23:e100. https://doi.org/10.1016/S1470-2045(22)00060-2CrossRefPubMed

Bekaert S, Rocks N, Vanwinge C, Noel A, Cataldo D (2021) Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11–CCR3 pathway. Respir Res 22:61. https://doi.org/10.1186/s12931-021-01652-9CrossRefPubMedPubMedCentral

Boffetta P et al (2002) O6-Alkylguanine-DNA-alkyltransferase activity in peripheral leukocytes, smoking and risk of lung cancer. Cancer Lett 180:33–39. https://doi.org/10.1016/S0304-3835(02)00014-9CrossRefPubMed

Bonapace L et al (2014) Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515:130–133. https://doi.org/10.1038/nature13862CrossRefPubMed

Bose S (2015) Triple-negative breast carcinoma: morphologic and molecular subtypes. Adv Anat Pathol 22:306–313. https://doi.org/10.1097/PAP.0000000000000084CrossRefPubMed

Bouchet M et al (2020) ERRα expression in bone metastases leads to an exacerbated antitumor immune response. Can Res 80:2914–2926. https://doi.org/10.1158/0008-5472.CAN-19-3584CrossRef

BRASIL (2019) PORTARIA CONJUNTA N^o 5, DE 18 DE ABRIL DE 2019. www.gov.br/conitec/pt-br/midias/protocolos/ddt/ddt-carcinoma-de-mama_portaria-conjunta-n-5.pdf

Cardoso F et al (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194–1220. https://doi.org/10.1093/annonc/mdz173CrossRefPubMed

Chavey C et al (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9:R15. https://doi.org/10.1186/bcr1648CrossRefPubMedPubMedCentral

Chen D, Zhang F, Ren H, Luo J, Wang S (2017) Role of cytokines and chemokines in alcohol-induced tumor promotion. Onco Targets Ther 10:1665–1671. https://doi.org/10.2147/OTT.S129781CrossRefPubMedPubMedCentral

Chen W et al (2018) CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer Hrsg. Connie Eaves. PLOS Biol 16:e2005869. https://doi.org/10.1371/journal.pbio.2005869CrossRefPubMedPubMedCentral

Cheng N-L et al (2015) MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age. Aging Cell 14:200–208. https://doi.org/10.1111/acel.12294CrossRefPubMedPubMedCentral

Cheng R et al (2020) Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells. Oncogene 39:1543–1556. https://doi.org/10.1038/s41388-019-1084-zCrossRefPubMed

Chiu J-H et al (2020) MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation. Sci Rep 10:8060. https://doi.org/10.1038/s41598-020-64950-0CrossRefPubMedPubMedCentral

de Amorim JSC et al (2020) Inflammatory markers associated with fall recurrence and severity: The Bambuí Cohort Study of Aging. Exp Gerontol 132:110837. https://doi.org/10.1016/j.exger.2020.110837CrossRefPubMed

Denkert C et al (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative primary breast cancers. J Clin Oncol 33:983–991. https://doi.org/10.1200/JCO.2014.58.1967CrossRefPubMed

Dieci MV et al (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25:611–618. https://doi.org/10.1093/annonc/mdt556CrossRefPubMedPubMedCentral

Duckworth BC et al (2021) Effector and stem-like memory cell fates are imprinted in distinct lymph node niches directed by CXCR3 ligands. Nat Immunol 22:434–448. https://doi.org/10.1038/s41590-021-00878-5CrossRefPubMed

Farmaki E, Kaza V, Papavassiliou AG, Chatzistamou I, Kiaris H (2017) Induction of the MCP chemokine cluster cascade in the periphery by cancer cell-derived Ccl3. Cancer Lett 389:49–58. https://doi.org/10.1016/j.canlet.2016.12.028CrossRefPubMed

Filho OM et al (2021) Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncol 7:603. https://doi.org/10.1001/jamaoncol.2020.7310CrossRefPubMed

Franzén B et al (2019) Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol 13:376–391. https://doi.org/10.1002/1878-0261.12410CrossRefPubMedPubMedCentral

Gantsev SK et al (2013) The role of inflammatory chemokines in lymphoid neoorganogenesis in breast cancer. Biomed Pharmacother 67:363–366. https://doi.org/10.1016/j.biopha.2013.03.017CrossRefPubMed

Gocher AM, Workman CJ, Vignali DAA (2022) Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22:158–172. https://doi.org/10.1038/s41577-021-00566-3CrossRefPubMed

Hadadi E et al (2020) Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun 11:3193. https://doi.org/10.1038/s41467-020-16890-6CrossRefPubMedPubMedCentral

Herishanu Y, Rogowski O, Polliack A, Marilus R (2006) Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 76:516–520. https://doi.org/10.1111/j.1600-0609.2006.00658.xCrossRefPubMed

Hilborn E et al (2014) C-X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients. Breast Cancer Res Treat 145:73–82. https://doi.org/10.1007/s10549-014-2933-7CrossRefPubMedPubMedCentral

Hu G-N et al (2018) Correlation between CCL4 gene polymorphisms and clinical aspects of breast cancer. Int J Med Sci 15:1179–1186. https://doi.org/10.7150/ijms.26771CrossRefPubMedPubMedCentral

Hu C et al (2021) A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 384:440–451. https://doi.org/10.1056/NEJMoa2005936CrossRefPubMedPubMedCentral

Ibrahim SA et al (2017) Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer 16:57. https://doi.org/10.1186/s12943-017-0621-zCrossRefPubMedPubMedCentral

Karnoub AE et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563. https://doi.org/10.1038/nature06188CrossRefPubMed

Li Z, Hu P, Tu J, Yu N (2016) Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget 7:65024–65033. https://doi.org/10.18632/oncotarget.11344CrossRefPubMedPubMedCentral

Li S et al (2020) Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer. NPJ Precis Oncol 4:25. https://doi.org/10.1038/s41698-020-00131-6CrossRefPubMedPubMedCentral

Li Li et al (2021) Peripheral blood leukocytes and platelets serve as prognostic factors in breast cancer. Cancer Biother Radiopharm 36:167–173. https://doi.org/10.1089/cbr.2019.3032CrossRefPubMed

Liu X et al (2018) Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer. World J Surg Oncol 16:82. https://doi.org/10.1186/s12957-018-1380-zCrossRefPubMedPubMedCentral

Miyashita M et al (2015) Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 17:124. https://doi.org/10.1186/s13058-015-0632-xCrossRefPubMedPubMedCentral

Mohamed HT et al (2020) IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2. Toxicol Appl Pharmacol 401:115092. https://doi.org/10.1016/j.taap.2020.115092CrossRefPubMed

Montella F, Lopardo V, Vecchione C, Puca AA, Ciaglia E (2021) High TARC plasma levels confer protection to long living individuals by inducing M2 profile. Cytokine 137:155305. https://doi.org/10.1016/j.cyto.2020.155305CrossRefPubMed

Nie G et al (2021) Tumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: Suppression by Danirixin. Int Immunopharmacol 95:107153. https://doi.org/10.1016/j.intimp.2020.107153CrossRefPubMed

Ntanasis-Stathopoulos I, Fotiou D und Terpos E (2020) CCL3 Signaling in the Tumor Microenvironment. In: Tumor Microenvironment, Bd. 1231, Hrsg. Alexander Birbrair, 13–21. Cham: Springer International Publishing. https://doi.org/10.1007/978-3-030-36667-4_2

Paccagnella M et al (2022) Circulating cytokines in metastatic breast cancer patients select different prognostic groups and patients who might benefit from treatment beyond progression. Vaccines 10:78. https://doi.org/10.3390/vaccines10010078CrossRefPubMedPubMedCentral

Pitt JM et al (2016) Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 27:1482–1492. https://doi.org/10.1093/annonc/mdw168CrossRefPubMed

Racioppi L et al (2019) CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. Nat Commun 10:2450. https://doi.org/10.1038/s41467-019-10424-5CrossRefPubMedPubMedCentral

Razis E et al (2020) The role of CXCL13 and CXCL9 in early breast cancer. Clin Breast Cancer 20:e36–e53. https://doi.org/10.1016/j.clbc.2019.08.008CrossRefPubMed

Romero-Moreno R et al (2019) The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat Commun 10:4404. https://doi.org/10.1038/s41467-019-12108-6CrossRefPubMedPubMedCentral

Shah K, Ignacio A, McCoy KD, Harris NL (2020) The emerging roles of eosinophils in mucosal homeostasis. Mucosal Immunol 13:574–583. https://doi.org/10.1038/s41385-020-0281-yCrossRefPubMed

Shield KD, Soerjomataram I, Rehm J (2016) Alcohol use and breast cancer: a critical review. Alcoholism 40:1166–1181. https://doi.org/10.1111/acer.13071CrossRefPubMed

Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267:271–285. https://doi.org/10.1016/j.canlet.2008.03.018CrossRefPubMed

Thomas JK, Mir H, Kapur N, Bae S, Singh S (2019) CC chemokines are differentially expressed in Breast Cancer and are associated with disparity in overall survival. Sci Rep 9:4014. https://doi.org/10.1038/s41598-019-40514-9CrossRefPubMedPubMedCentral

Triola MF, Triola MF (2012) Elementary statistics technology update, 11th edn. Pearson Education, Boston

Van Der Zalm IJB et al (2020) Obesity-associated T-cell and macrophage activation improve partly after a lifestyle intervention. Int J Obes 44:1838–1850. https://doi.org/10.1038/s41366-020-0615-6CrossRef

Wang J, He Q, Shao YG, Ji M (2013) Chemokines fluctuate in the progression of primary breast cancer. Eur Rev Med Pharmacol Sci 17:596–608PubMed

Wang G-Z et al (2015) Tobacco smoke induces production of chemokine CCL20 to promote lung cancer. Cancer Lett 363:60–70. https://doi.org/10.1016/j.canlet.2015.04.005CrossRefPubMed

Wang N et al (2018a) CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling. Cell Death Dis 9:880. https://doi.org/10.1038/s41419-018-0876-3CrossRefPubMedPubMedCentral

Wang Y et al (2018b) HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk. J Clin Investig 128:5235–5250. https://doi.org/10.1172/JCI99974CrossRefPubMedPubMedCentral

Wang R-X, Ji P, Gong Y, Shao Z-M, Chen S (2020) Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study. Breast Cancer Res Treat 181:561–570. https://doi.org/10.1007/s10549-020-05660-zCrossRefPubMed

Wong P-P et al (2020) Cancer burden is controlled by mural cell-β3-integrin regulated crosstalk with tumor cells. Cell 181:1346-1363.e21. https://doi.org/10.1016/j.cell.2020.02.003CrossRefPubMed

Wu X, Sun A, Yu W, Hong C, Liu Z (2020) CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation. Mol Cell Endocrinol 512:110866. https://doi.org/10.1016/j.mce.2020.110866CrossRefPubMed

Zhang F, Liu S (2020) Mechanistic insights of adipocyte metabolism in regulating breast cancer progression. Pharmacol Res 155:104741. https://doi.org/10.1016/j.phrs.2020.104741CrossRefPubMed

Zheng Z, Jia S, Shao C, Shi Y (2020) Irradiation induces cancer lung metastasis through activation of the cGAS–STING–CCL5 pathway in mesenchymal stromal cells. Cell Death Dis 11:326. https://doi.org/10.1038/s41419-020-2546-5CrossRefPubMedPubMedCentral

Titel: The elusive Luminal B breast cancer and the mysterious chemokines
verfasst von: Rogério Agenor de Araújo
Felipe Andrés Cordero da Luz
Eduarda da Costa Marinho
Camila Piqui Nascimento
Thais Rezende Mendes
Etelvina Rocha Tolentino Mosca
Lara de Andrade Marques
Patrícia Ferreira Ribeiro Delfino
Rafael Mathias Antonioli
Ana Cristina Araújo Lemos da Silva
Maria Luiza Gonçalves dos Reis Monteiro
Morun Bernardino Neto
Marcelo José Barbosa Silva
Publikationsdatum: 17.07.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 14/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05094-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The elusive Luminal B breast cancer and the mysterious chemokines